Optiray 350- Ioversol injection Prescribing Information
OPTIRAY is indicated for intravascular use only
Dosage and Administration, Important Dosage and Administration Instructions (2.1) 11/2020
OPTIRAY is indicated for:
Injection: clear, colorless to pale yellow solutions containing no undissolved solids, available in the following strengths and multiple-dose containers:
| Imaging Product | mg of ioversol per mL | mg of organically bound iodine per mL | Imaging Bulk Pack Presentation |
| OPTIRAY 300 (Ioversol 64%) | 636 | 300 | Yes |
| OPTIRAY 320 (Ioversol 68%) | 678 | 320 | Yes |
| OPTIRAY 350 (Ioversol 74%) | 741 | 350 | Yes |
Symptomatic hyperthyroidism.
Severe cutaneous adverse reactions (SCAR) may develop from 1 hour to several weeks after intravascular contrast agent administration. These reactions include Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS). Reaction severity may increase and time to onset may decrease with repeat administration of a contrast agent; prophylactic medications may not prevent or mitigate severe cutaneous adverse reactions. Avoid administering OPTIRAY to patients with a history of a severe cutaneous adverse reaction to OPTIRAY.